跳至主要内容
临床试验/NCT00195689
NCT00195689已完成3 期

A Multi-Center Continuation Trial for Patients Completing Study M02-518 and M02-570 of the Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients With Moderate to Severely Active Psoriatic Arthritis

Abbott2 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2003年8月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
Abbott
入组人数
400
试验地点
2
主要终点
Safety parameters

研究概览

简要总结

The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in treatment of moderate to severely active psoriatic arthritis

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject completed study M02-518 or M02-570

排除标准

  • Subject prematurely discontinued study M02-518 or M02-570
  • Female subject who is pregnant or breast-feeding or considering becoming pregnant
  • Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study

结局指标

主要结局

Safety parameters

ACR 20/50/70

PsARC

HAQ

SF-36

Disease progression measurements

FACTIT Fatigue Scale

次要结局

  • Clinical response indicators
  • Patient reported outcomes

研究者

发起方
Abbott
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验